1. Home
  2. INN vs YMAB Comparison

INN vs YMAB Comparison

Compare INN & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INN
  • YMAB
  • Stock Information
  • Founded
  • INN 2010
  • YMAB 2015
  • Country
  • INN United States
  • YMAB United States
  • Employees
  • INN N/A
  • YMAB N/A
  • Industry
  • INN Real Estate Investment Trusts
  • YMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • INN Real Estate
  • YMAB Health Care
  • Exchange
  • INN Nasdaq
  • YMAB Nasdaq
  • Market Cap
  • INN 692.3M
  • YMAB 631.1M
  • IPO Year
  • INN 2011
  • YMAB 2018
  • Fundamental
  • Price
  • INN $6.41
  • YMAB $15.55
  • Analyst Decision
  • INN Hold
  • YMAB Strong Buy
  • Analyst Count
  • INN 1
  • YMAB 8
  • Target Price
  • INN N/A
  • YMAB $21.38
  • AVG Volume (30 Days)
  • INN 663.9K
  • YMAB 171.6K
  • Earning Date
  • INN 11-04-2024
  • YMAB 11-08-2024
  • Dividend Yield
  • INN 4.94%
  • YMAB N/A
  • EPS Growth
  • INN N/A
  • YMAB N/A
  • EPS
  • INN 0.07
  • YMAB N/A
  • Revenue
  • INN $736,287,000.00
  • YMAB $86,546,000.00
  • Revenue This Year
  • INN $0.45
  • YMAB $10.69
  • Revenue Next Year
  • INN $1.46
  • YMAB $19.72
  • P/E Ratio
  • INN $89.68
  • YMAB N/A
  • Revenue Growth
  • INN 0.72
  • YMAB 1.84
  • 52 Week Low
  • INN $5.66
  • YMAB $4.69
  • 52 Week High
  • INN $7.22
  • YMAB $20.90
  • Technical
  • Relative Strength Index (RSI)
  • INN 49.71
  • YMAB 63.90
  • Support Level
  • INN $5.94
  • YMAB $14.19
  • Resistance Level
  • INN $6.52
  • YMAB $15.08
  • Average True Range (ATR)
  • INN 0.17
  • YMAB 0.67
  • MACD
  • INN 0.01
  • YMAB 0.06
  • Stochastic Oscillator
  • INN 77.50
  • YMAB 76.19

About INN Summit Hotel Properties Inc.

Summit Hotel Properties Inc is a U.S.-based hotel investment company focusing on select-service hotels in the upscale and upper-midscale properties in the U.S. Substantially all of Summit's assets are held and operated by its Operating Partnership, Summit Hotel OP, LP, in which the company holds general and limited partnership interests. The firm has one segment in activities related to investing in real estate. Summit's revenue streams include Room and Other hotel operations revenue. Room comprises the majority of total revenues. The firm's hotels are located in various markets, such as corporate offices, retail centers, airports, state capitols, convention centers, and leisure attractions. Summit's hotels operate under brands, including Marriott, Hilton, Hyatt, and Holiday Inn.

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Share on Social Networks: